

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: 30 April 2020

Electronic Signature for Jill Ann Mello, Ph.D.: /Jill Ann Mello/

PTO-1382 (Rev. 01-2017)

Approved for use through 08/31/2019. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES RECEIVING OFFICE (RO/US)

Priority Mail Express Mailing Label No.:	Date of Deposit: 30 April 2020
File Reference No.: 130197-00320	International Application No. (If known): Not Yet Assigned
Customer Number ¹ : 86738	Earliest Priority Date Claimed (dd/mm/yyyy): 30 April 2019
Title of Invention: FRATAXIN-SENSITIVE MARKERS FOR DETERMINING EFFECTIVENESS OF FRATAXIN REPLACEMENT THERAPY	
Applicant: Chondrial Therapeutics, Inc.	

¹Customer Number will allow access to the application in Private PAIR but cannot be used to establish or change the correspondence address.

This is a new International Application

SCREENING DISCLOSURE INFORMATION:

In order to assist in screening the accompanying international application for purposes of determining whether a license for foreign transmittal should and could be granted and for other purposes, the following information is supplied. (check all boxes as apply):

The invention disclosed was **not** made in the United States of America.

There is no prior U.S. application relating to this invention.

The following prior U.S. application(s) contain subject matter which is related to the invention disclosed in the attached international application. (NOTE: priority to these applications may or may not be claimed on the Request (form PCT/RO/101) and this listing does not constitute a claim for priority.)

application no.	62/840,878	filed on	30 April 2019
application no.		filed on	

The present international application contains additional subject matter not found in the prior U.S. application(s) identified above.

The additional subject matter is found on pages Throughout

and DOES NOT ALTER MIGHT BE CONSIDERED TO ALTER the general nature of the invention in a manner which would require the U.S. application to have been made available for inspection by the appropriate defense agencies under 35 U.S.C. 181 and 37C.F.R. 5.15.

Itemized list of contents & entity status

Sheets of Request form: 8	Check no.:
Sheets of description (excluding sequence listing): 98	Return receipt postcard:
Sheets of claims: 10	Power of attorney:
Sheets of abstract: 1	Certified copy of priority document (specify):
Sheets of drawings: 12	PTO/SB15A or B or equivalent:
Sheets (paper or pdf) of sequence listing:	Other (specify): PCT Fee Calculation Sheet
Sequence listing text file: <input type="checkbox"/> CD or diskette <input checked="" type="checkbox"/> via EFS-Web	
<input checked="" type="checkbox"/> Applicant asserts small entity status. See 37 CFR 1.27. If this written assertion is made by the applicant, all applicants must sign (37 C.F.R. §1.42)	
<input type="checkbox"/> Applicant certifies micro entity status. See 37 CFR 1.29. Applicant must attach form PTO/SB/15A or B or equivalent.	

The person signing this form is:	<input type="checkbox"/> Applicant	Jill Ann Mello, Ph.D.
	<input checked="" type="checkbox"/> Attorney/Agent Registration No. <u>55,450</u>	
	<input type="checkbox"/> Common Representative	/Jill Ann Mello/ Signature